The goal of the study is to learn what happens to levels of nemtabrutinib (MK-1026) in a healthy person's body over time. Researchers will compare what happens to nemtabrutinib in the body when it is given with or without another medicine called diltiazem.
Age range
18 Years – 55 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Nemtabrutinib
Timeframe: Up to approximately 4 weeks
Maximum Plasma Concentration (Cmax) of Nemtabrutinib
Timeframe: Up to approximately 4 weeks
Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of Nemtabrutinib
Timeframe: Up to approximately 4 weeks
Time to Maximum Plasma Concentration (Tmax) of Nemtabrutinib
Timeframe: Up to approximately 4 weeks
Apparent Terminal Half-life (t1/2) of Nemtabrutinib
Timeframe: Up to approximately 4 weeks
Apparent Clearance (CL/F) of Nemtabrutinib
Timeframe: Up to approximately 4 weeks
Volume of Distribution During Terminal Phase (Vz/F) of Nemtabrutinib
Timeframe: Up to approximately 4 weeks